Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
08:30am, Monday, 10'th Jun 2024
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of car
NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
08:30am, Tuesday, 28'th May 2024
Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavi
NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
08:11pm, Tuesday, 14'th May 2024
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Company's Chief Business Officer Stephen Willard - Chief Executive
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 14'th May 2024
2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional invest
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 14'th May 2024
2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional invest
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
08:30am, Wednesday, 08'th May 2024
RADNOR, Pa. , May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will par
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
04:01pm, Tuesday, 07'th May 2024
RADNOR, Pa. , May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will rele
Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size
NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relativ
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
07:01pm, Thursday, 25'th Apr 2024
The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
07:06pm, Friday, 19'th Apr 2024
In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
08:56am, Thursday, 18'th Apr 2024
NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. NRX Pharmaceuticals is selling
The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter Four upcoming milestones expected: data from trials in Suicida
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
08:30am, Thursday, 18'th Apr 2024
RADNOR, Pa. , April 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
04:45pm, Wednesday, 17'th Apr 2024
RADNOR, Pa. , April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it inte
